Angioslide announced on 3 January 2013 the closing of US$6.3 million financing led by new investor TriVentures. In addition Biostar joined returning investors Viola Partners, Agate and XT Investments (formerly Ofer HT) to complete the round.
“Proceeds from this series C round will be used to continue US market expansion, improve our product offering and validate the technology in additional vascular beds,” said Lihu Avitov, Angioslide CEO. “The financing will help us fuel our growth. We are excited to have TriVentures join our efforts and appreciate the ongoing support from Viola Partners, Agate and XT Investments.”
Angioslide is transforming peripheral angioplasty by combining percutaneous transluminal angioplasty balloon intervention with debris capture and removal. The Proteus device removes some of the embolic particles released during peripheral interventions enabling physicians to improve procedural outcomes in challenging interventions. Angioslide’s above-the-knee product line was recently expanded to include a below-the-knee, low-profile 0.014’’ platform.
“Angioslide is a very exciting opportunity that can truly help peripheral arterial disease patients reconstitute their vascular flow,” said Michal Geva, co-founder and a managing partner of TriVentures. “This is one of TriVentures’ first investments in which the clinical, regulatory and commercial challenges are mitigated, and we look forward to working with the team in bringing this technology to expanded commercialisation in the USA.”